Peptides and methods for the treatment of diabetes
AssigneePhoenix Alpha
InventorsLuc Vander Elst, Vincent Carlier, Jean-Marie Saint-Remy
Life of this patent
Estimating the term…
Abstract
The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG [SEQ ID NO: 26] and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.
Claims11
An in vitro method for the generation of a population of cytolytic CD4+ T cells against antigen presenting cells (APC) presenting insulin epitopes, comprising the steps of:
- providing peripheral blood cells;
- contacting said cells in vitro with an isolated immunogenic peptide comprising the amino acid sequence of HCXX[CST]SLQPLALEGSLQK [SEQ ID NO:7] or H[CST]XXCSLQPLALEGSLQK [SEQ ID NO:8] wherein X stands for any amino acid, and wherein the peptide has a length of between 12 and 50 amino acids;
- and
- expanding said cells in the presence of IL-2.
A pharmaceutical composition comprising (i) an immunogenic peptide comprising the amino acid sequence HCXX[CST]SLQPLALEGSLQK [SEQ ID NO:
- 7] or H[CST]XXCSLQPLALEGSLQK [SEQ ID NO:8] and (ii) a pharmaceutically acceptable carrier, wherein X stands for any amino acid, the immunogenic peptide has a length of between 12 and 50 amino acids, and the pharmaceutical composition is suitable for subcutaneous administration.
A method of treating type 1 diabetes comprising subcutaneously administering to a subject in need thereof a therapeutically sufficient amount of an immunogenic peptide comprising the amino acid sequence of HCXX[CST]SLQPLALEGSLQK [SEQ ID NO:7] or H[CST]XXCSLQPLALEGSLQK [SEQ ID NO:8], wherein X stands for any amino acid, and wherein the peptide has a length of between 12 and 50 amino acids.
Dependencies are inferred from the claim text.